Menu Search
Equities

Vanda Pharmaceuticals Inc

VM4:DEU

Vanda Pharmaceuticals Inc

Actions
  • Price (EUR)4.80
  • Today's Change0.18 / 3.90%
  • Shares traded0.00
  • 1 Year change+50.94%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

  • Revenue in USD (TTM)190.86m
  • Net income in USD-16.39m
  • Incorporated2002
  • Employees203.00
  • Location
    Vanda Pharmaceuticals IncSUITE 300E, 2200 PENNSYLVANIA AVE NWWASHINGTON 20037United StatesUSA
  • Phone+1 (202) 734-3400
  • Fax+1 (202) 296-1450
  • Websitehttps://www.vandapharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		VNDA:NMQ since
announced		Transaction
value
Actelion Pharmaceuticals Ltd-PONVORYDeal completed07 Dec 202307 Dec 2023Deal completed28.47%100.00m
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.